Replies to post #25472 on Relief Therapeutics Holding AG (RLFTF)

[mc67]

Yes, " Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19."